Dr. Abud Bakri

Anytime.

Because the idea with these bioregulators, unlike, you know, a GLP-1 drug that you take today and have the effect for the next week, the idea from the Cavendish model is that you take these and then you accrue benefits when you're off of them.

Like you notice with pinelion, you took pinelion for a day or two or three days a month, and you had effects until you took the next dose.

So the idea is, can you accrue benefits from these compounds as they upregulate or downregulate certain genetic pathways in a more favorable state, and then keep those effects

later on.

So in the Cavendish seminal work was his 15 year longevity study.

He got people in nursing homes, two groups, one of them got epithelon in the form of epithelamine, which is the whole pineal gland extract.

And then a thymus peptide called thymulin, not thymulin.

There's two different peptides.

A lot of people can confuse them.

Every peptide website confuses them.

But

He injected them for 15 years, like a 10- or 20-day course per year, just beginning of the year, middle of the year, and that's it.

And they had a significant lower mortality when it came to cardiovascular disease, infectious risk, and for cancers.

So Russian study, caveat.

But that would be the most interesting longevity study I've seen done, if accurate, if true, because he was able to take nursing home patients, give them peptides for, you know,

very small amount of the year, and yet they accrued benefits the rest of the year.

The Russians say epithalon.

It's the way they say it, but it's spelled with a T-H.

Okay.